Peptides of pineal gland and thymus prolong human life.

Khavinson VKh, Morozov VG. Neuroendocrinol Lett. 2003.

Organ: thymus-immune · Type: clinical · Peptides: Thymalin, Epithalamin

A 6–8-year clinical assessment of Thymalin and Epithalamin in 266 elderly people; PubMed tags the paper as an RCT, but the English abstract does not describe randomization or blinding.

Editorial summary of a 2003 original article in Neuroendocrinology Letters. Long-term clinical series from St. Petersburg and Kiev gerontology institutes. Public pages cite PubMed only. Read the paper: PMID 14523363.

Methods

The authors clinically assessed thymic (Thymalin) and pineal (Epithalamin) peptide bioregulators in 266 elderly and older persons over 6–8 years. The preparations were applied for the first 2–3 years of observation; a separate group received Thymalin plus Epithalamin annually for 6 years. PubMed indexes the article as a randomized controlled trial, but the English abstract does not describe randomization, blinding, or allocation. Treat the design as a long-term clinical series unless the primary text shows otherwise. This page does not reprint the publisher PDF.

Findings

The authors report improved indices of cardiovascular, endocrine, immune, and nervous systems, homeostasis, and metabolism, with a 2.0–2.4-fold decrease in acute respiratory disease and reduced clinical manifestations of ischemic heart disease, hypertension, deforming osteoarthrosis, and osteoporosis versus control. They report mortality lower by 2.0–2.1-fold with Thymalin, 1.6–1.8-fold with Epithalamin, 2.5-fold with both, and 4.1-fold in the group treated annually for 6 years, compared with control.

Those mortality ratios are the authors’ report from this series. This is not independently replicated evidence that these preparations prolong human life, and it is not a product claim. Follow the PMID.